The 36-month beta value for CRNX is also noteworthy at 0.66. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for CRNX is 72.87M, and at present, short sellers hold a 7.17% of that float. The average trading volume of CRNX on May 08, 2024 was 806.40K shares.
CRNX) stock’s latest price update
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) has experienced a rise in its stock price by 4.51 compared to its previous closing price of 47.66. However, the company has seen a gain of 10.57% in its stock price over the last five trading days. GlobeNewsWire reported 2024-05-02 that SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024, after the close of the U.S. financial markets. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
CRNX’s Market Performance
Crinetics Pharmaceuticals Inc (CRNX) has seen a 10.57% rise in stock performance for the week, with a 6.18% gain in the past month and a 31.84% surge in the past quarter. The volatility ratio for the week is 4.02%, and the volatility levels for the past 30 days are at 4.45% for CRNX.. The simple moving average for the past 20 days is 11.67% for CRNX’s stock, with a 51.75% simple moving average for the past 200 days.
Analysts’ Opinion of CRNX
Many brokerage firms have already submitted their reports for CRNX stocks, with Citigroup repeating the rating for CRNX by listing it as a “Buy.” The predicted price for CRNX in the upcoming period, according to Citigroup is $68 based on the research report published on March 06, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRNX reach a price target of $50. The rating they have provided for CRNX stocks is “Overweight” according to the report published on January 16th, 2024.
Jefferies gave a rating of “Hold” to CRNX, setting the target price at $35 in the report published on December 21st of the previous year.
CRNX Trading at 13.19% from the 50-Day Moving Average
After a stumble in the market that brought CRNX to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.46% of gains for the given period.
Volatility was left at 4.45%, however, over the last 30 days, the volatility rate increased by 4.02%, as shares surge +7.12% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +21.50% upper at present.
During the last 5 trading sessions, CRNX rose by +9.15%, which changed the moving average for the period of 200-days by +165.21% in comparison to the 20-day moving average, which settled at $44.77. In addition, Crinetics Pharmaceuticals Inc saw 39.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRNX starting from Pizzuti Dana, who sale 14,375 shares at the price of $44.47 back on Apr 15 ’24. After this action, Pizzuti Dana now owns 27,786 shares of Crinetics Pharmaceuticals Inc, valued at $639,256 using the latest closing price.
Struthers Richard Scott, the President & CEO of Crinetics Pharmaceuticals Inc, sale 40,951 shares at $49.17 during a trade that took place back on Apr 04 ’24, which means that Struthers Richard Scott is holding 237,835 shares at $2,013,561 based on the most recent closing price.
Stock Fundamentals for CRNX
Current profitability levels for the company are sitting at:
- -55.47 for the present operating margin
- 0.67 for the gross margin
The net margin for Crinetics Pharmaceuticals Inc stands at -52.96. The total capital return value is set at -0.38. Equity return is now at value -50.16, with -43.45 for asset returns.
Based on Crinetics Pharmaceuticals Inc (CRNX), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -3.22. The debt to equity ratio resting at 0.1. The interest coverage ratio of the stock is 112.26.
Currently, EBITDA for the company is -221.51 million with net debt to EBITDA at 0.01. When we switch over and look at the enterprise to sales, we see a ratio of 971.1. The receivables turnover for the company is 0.43for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.07.
Conclusion
In summary, Crinetics Pharmaceuticals Inc (CRNX) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
